Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase III, Multi-Center Controlled Trial With Stratified Randomization Comparing The Efficacy Of Interleukin-2 (IL-2) Plus Histamine Dihydrochloride (HDC) Versus IL-2 Alone To Increase The Duration Of Survival In Patients With AJCC Stage IV Malignant Melanoma With Hepatic Metastasis

NCT00039234 is registered in ClinicalTrials.gov with Maxim Pharmaceuticals as lead sponsor.

NCT NCT00039234
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00039234 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase III, Multi-Center Controlled Trial With Stratified Randomization Comparing The Efficacy Of Interleukin-2 (IL-2) Plus Histamine Dihydrochloride (HDC) Versus IL-2 Alone To Increase The Duration Of Survival In Patients With AJCC Stage IV Malignant Melanoma With Hepatic Metastasis
Lead sponsor
Maxim Pharmaceuticals
Phase
Phase 3
Overall status
Unknown status
Start date
September 30, 2002
Completion date
Not reported
Enrollment
Not reported
Sites
19

Conditions

As the registry lists them; a condition with its own page is linked.

melanoma (skin), metastatic cancer